Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449787 · ClinicalTrials.gov registry record · Phase 4
Comparing Naproxen to Sumatriptan for Emergency Headache Patients
A Phase 4 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 401
- Enrollment target
NCT00449787: Completed Phase 4 study, sponsored by Montefiore Medical Center.
NCT00449787 is a Phase 4 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 401 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00449787, a Phase 4 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 401 participants
- Enrollment target
Study Summary
2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment. The goal of this study is to compare two medications, naproxen and sumatriptan, to determine which is better for the treatment of recurrent headache within 24 hours of emergency department discharge.
Primary Outcome
Within 48 hours of ED discharge, participants were allowed to take the investigational medication. At the moment they took the investigational medication, they were asked to record a number from 0 to 10, which represented their headache. 0 signified no pain and 10 signified the worse pain imaginable. Two hours later, participants were asked again to record their pain on a scale from 0 to 10. The outcome is the change in pain between baseline and two hours and will be a number between 0 and 10.
Interventions
- DRUG Naproxen
- DRUG Sumatriptan 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
What the finished NCT00449787 record still lists
NCT00449787 is an interventional study that assigns participants to a tested intervention. The registered 401 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Naproxen is the first listed.
NCT00449787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00449787 about?
NCT00449787 is a clinical study titled "Comparing Naproxen to Sumatriptan for Emergency Headache Patients". 2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment. The goal of this study is to compare two medications, naproxen and sumatriptan, to determine which is better for th...
What is the current status of trial NCT00449787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 401 participants. The study started on 2007-03. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00449787?
The interventions under investigation include: Naproxen (DRUG), Sumatriptan 100 mg (DRUG).
Who is sponsoring clinical trial NCT00449787?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00449787's enrollment target sits among peer trials
401 210th of 2000 higher than 1,790 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia